Here is the design of a clinical trial:

Official Title: Skeletal Muscle Hypertrophy and Cardio-Metabolic Benefits After Spinal Cord Injury

Included conditions:
- Spinal Cord Injuries

Study Armgroups:
- {'label': 'NMES+FES group', 'type': 'EXPERIMENTAL', 'description': 'NMES+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of surface NMES and ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks +3 weeks for measurements.', 'interventionNames': ['Device: NMES+FES']}
- {'label': 'Control+FES group', 'type': 'EXPERIMENTAL', 'description': 'Control+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of passive leg extension/flexion with no ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks+3 weeks for measurements.', 'interventionNames': ['Device: Control+FES']}

Interventions:
- {'type': 'DEVICE', 'name': 'NMES+FES', 'description': '12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.', 'armGroupLabels': ['NMES+FES group'], 'otherNames': ['(NMES; Theratouch)+(FES; RTI300 Bike)']}
- {'type': 'DEVICE', 'name': 'Control+FES', 'description': '12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.', 'armGroupLabels': ['Control+FES group'], 'otherNames': ['Control+(FES; RTI300 Bike)']}

Primary Outcomes:
- {'measure': 'Glucose uptake', 'description': 'by measuring glucose effectiveness', 'timeFrame': '24 weeks'}
- {'measure': 'Insulin Sensitivity', 'description': 'By performing frequent blood drawing of 32 samples over 3 hour period while the patient is fasting.', 'timeFrame': '24 weeks'}
- {'measure': 'Oxygen Uptake', 'timeFrame': '24 weeks'}

Please estimate the sample size based on the assumption: 
The correlation between pre- and post-treatment measurements is assumed to be 0.3735 for glucose effectiveness and 0.4 for insulin sensitivity and VO2. The study aims for 90% power with a Type-1 error rate of 0.05. A 20% dropout rate is considered.
Sample size
        We have acquired pilot data for all outcomes of this project. Glucose effectiveness possesses the smallest effect size from baseline to follow-up with NMES-RT showing a mean baseline effectiveness of 0.01716 and post-treatment mean of 0.02258. Cohenâs f was found to be 0.271 using a sample variance of 0.0001 [25]. Assuming the correlation between the pre- and post-treatment measurements is 0.3735 and three total measurements are acquired, 38 individuals will need to complete the study at 90% power using a Type-1 error rate of 0.05. At least 48 participants will need to be recruited, adjusting for a 20% dropout rate. All sample sizes were calculated using the software G*Power (V3.1.9.2). A sample size of 24 was calculated using insulin sensitivity data without regard to dropout rate.
        Other factors, such as insulin sensitivity and VO2, are considered; each representing larger effect sizes than glucose effectiveness (fâ=â0.313 and fâ=â0.432, respectively). Our study would result in a power of 97.51% and 99.82% for observing the baseline to follow-up difference between the NMES + FES and Control + FES groups, provided the correlation between baseline and follow-up measurements are 0.4 for the outcomes.